Contact us
Text Size
Large
Small
[This site uses JavaScript. Please do effectively and see the setting of JavaScript.]
About Takeda
Responsibility
Patient Assistance Program
Community Involvement
Culture of Compliance
R&D
Products
Newsroom
2010
2009
2008
2007
2006
2005
2004
2003
Press Center
Careers
Jobs
Submit Resume
Home
>
Newsroom
>
2005
2010
2009
2008
2007
2006
2005
2004
2003
Press Center
News and Press Releases
2005
November 22, 2005
Takeda Pharmaceuticals North America Names Chief Compliance Officer
November 16, 2005
New Data Shows Takeda's ACTOS® (pioglitazone HCl) Reduced Heart Attacks by 28 Percent in People with Type 2 Diabetes
October 26, 2005
Talented Local Students Receive Scholarships for Scientific Advancement Takeda Sponsors 2005-06 ARCS Scholarship Recipients
September 20, 2005
PROactive Study Shows Takeda's ACTOS ® (pioglitazone HCl) Reduced Heart Attacks, Strokes and Deaths in Patients With Type 2 Diabetes
August 29, 2005
ACTOplus metTM (pioglitazone HCl and metformin HCl) Approved by the FDA for Type 2 Diabetes
July 22, 2005
FDA Approved ROZEREM TM(ramelteon), First and Only Non-Scheduled Prescription Sleep Medication
June 11, 2005
Diabetes Drug ACTOS® (pioglitazone HCl) Showed Anti-Inflammatory Effects
May 17, 2005
Older Adults with Insomnia Report Falling Asleep Faster with Ramelteon
May 17, 2005
Phase III Clinical Program Evaluates Lubiprostone for the Treatment of Constipation-Predominant Irritable Bowel Syndrome
Page Top